1 Rauer S, Kastenbauer S. Neuroborreliose. Deutsche Gesellschaft für Neurologie [état au 21 mars 2018, en ligne depuis le 13 avril 2018]. Disponible sur:
https://www.dgn.org/leitlinien/3567-ll-030-071-2018-neuroborreliose
2 Stanek G, Fingerle V, Hunfeld KP, Jaulhac B, Kaiser R, Krause A, et al. Lyme borreliosis: Clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect. 2011;17:69–79.
3 Shapiro ED. Lyme Disease. N Engl J Med. 2014;370:1724–31.
4 Mygland A, Ljøstad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol. 2010;17:8–16.
5 Berglund J, Eitrem R, Ornstein K, Lindberg A, Ringér A, Elmrud H, et al. An epidemiologic study of Lyme disease in southern Sweden. N Engl J Med. 1995;333:1319–27.
6 Hansen K. Lebech AM. The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985–1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. BRAIN. 1992;115:399–423.
7 Ljøstad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol. 2008;7:690–5.
8 Bremell D, Dotevall L. Oral doxycycline for Lyme neuroborreliosis with symptoms of encephalitis, myelitis, vasculitis or intracranial hypertension. Eur J Neurol. 2014,21:1162–7.
9 Nemeth J, Bernasconi E, Heininger U, Abbas M, Nadal D, Strahm C, et al. for the Swiss Society for Infectious Diseases and the Swiss Society for Neurology. Update of the Swiss guidelines on post-treatment Lyme disease syndrome. Swiss Med Wkly. 2016;146:w14353.